1. Home
  2. PCM vs THAR Comparison

PCM vs THAR Comparison

Compare PCM & THAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PCM Fund Inc.

PCM

PCM Fund Inc.

HOLD

Current Price

$6.06

Market Cap

82.0M

Sector

Finance

ML Signal

HOLD

Logo Tharimmune Inc.

THAR

Tharimmune Inc.

HOLD

Current Price

$2.58

Market Cap

82.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PCM
THAR
Founded
1993
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
82.0M
82.7M
IPO Year
N/A
2022

Fundamental Metrics

Financial Performance
Metric
PCM
THAR
Price
$6.06
$2.58
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
29.1K
369.0K
Earning Date
01-01-0001
11-12-2025
Dividend Yield
11.68%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.88
$0.95
52 Week High
$10.20
$9.08

Technical Indicators

Market Signals
Indicator
PCM
THAR
Relative Strength Index (RSI) 33.81 50.42
Support Level $6.09 $2.20
Resistance Level $6.15 $2.62
Average True Range (ATR) 0.06 0.18
MACD -0.01 0.04
Stochastic Oscillator 4.35 67.27

Price Performance

Historical Comparison
PCM
THAR

About PCM PCM Fund Inc.

Pcm Fund Inc is a closed-end investment management company. Its investment objective is to seek current income as a primary focus and also capital appreciation. The Fund invests in agency-guaranteed mortgage-backed securities, private-label mortgage-backed securities, high-yield corporate debt securities, and commercial mortgage-backed securities.

About THAR Tharimmune Inc.

Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.

Share on Social Networks: